Detalhe da pesquisa
1.
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.
Int J Infect Dis
; 126: 164-173, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36403819
2.
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
Vaccine
; 40(31): 4220-4230, 2022 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691871